Key Results
Surprisingly, we found that oral NVP-BHG712 treatment significantly reduced bone loss in postmenopausal mice. In vitro osteoclast culture, it was found that this effect was achieved by inhibiting osteoclast differentiation and bone resorption. Meanwhile, NVP-BHG712 significantly decreased the expression of genes related to osteoclast differentiation, including CTSK, MMP9, CTR, IP3R1, IP3R3, and OC-STAMP.